Across TCGA pan-cancer cohorts, SPTLC1P2 RNA differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of SPTLC1P2’s most consistent transcriptional readouts.

The strongest signal is observed in colon adenocarcinoma (COAD), where SPTLC1P2 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types SPTLC1P2 is over-expressed in tumor, although a few such as ESCA and LUAD show the opposite, repressed pattern.

COAD, ESCA, and STAD are the cancer types where SPTLC1P2 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in SPTLC1P2 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
COAD	All	II,III,IV	+0.270	.039	2	view →
ESCA	Female	All	−0.446	<.001	1	view →
STAD	All	II,III,IV	+0.279	.019	1	view →
LUAD	Male	All	−0.240	.037	1	view →
LIHC	All	All	+0.041	.022	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

Exploration

Same gene, other analysis: SPTLC1P2 RNA expression & survival · all SPTLC1P2 data types